What is the history of Abetalipoproteinemia?

Abetalipoproteinemia was first described in 1950 by Dr. Bassen and Dr. Kornzweig, who identified it as a rare genetic disorder characterized by the inability to absorb dietary fats and fat-soluble vitamins. Understanding of Abetalipoproteinemia has evolved from a mysterious neurological syndrome to a manageable condition through high-dose vitamin supplementation and strict dietary fat restriction.

When was Abetalipoproteinemia first identified?

In 1950, ophthalmologist Abraham Kornzweig and neurologist Frank Bassen published a seminal report detailing an 18-year-old girl with atypical retinitis pigmentosa, acanthocytosis (spiked red blood cells), and neurological impairment. Initially known as Bassen-Kornzweig syndrome, the medical community eventually adopted the term Abetalipoproteinemia to reflect the complete absence of apolipoprotein B-containing lipoproteins in the blood.

How has our understanding of Abetalipoproteinemia evolved?

Early researchers struggled to connect the neurological symptoms with the patient's inability to absorb fat. Over decades, clinical observation revealed that the severe vitamin E deficiency inherent in Abetalipoproteinemia was the primary culprit behind the neurological and retinal damage. The identification of the MTTP gene mutation in the 1990s revolutionized the field, moving the diagnosis from purely clinical observation to precise molecular genetic testing.

What were the major milestones in managing Abetalipoproteinemia?

Before the 1960s, patients faced a grim prognosis with progressive disability. The medical landscape shifted significantly with the implementation of specific nutritional therapies:

• High-dose Vitamin E supplementation: Found to be critical in halting the progression of neurological and retinal symptoms.


• Low-fat diets: Introduced to mitigate the gastrointestinal distress caused by the inability to process long-chain triglycerides.


• Supplementation of Vitamins A, D, and K: Essential for preventing secondary complications like coagulopathy and bone disease.

How did modern genetics change the landscape of the disease?

The discovery that Abetalipoproteinemia is an autosomal recessive disorder caused by mutations in the MTTP gene allowed for accurate carrier testing and prenatal diagnosis. Today, 19 individuals within the DiseaseMaps.org community share their lived experiences, highlighting how awareness and early diagnosis—often made possible by modern genetic screening—prevent the severe systemic damage once associated with Abetalipoproteinemia.

Next steps

• Consult a metabolic specialist or a lipidologist to ensure your vitamin E levels are being monitored correctly.


• Join the DiseaseMaps.org community to connect with other families navigating Abetalipoproteinemia.


• Work with a specialized dietician to manage fat intake while ensuring adequate caloric and nutrient density.

Medical disclaimer: This content is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Abetalipoproteinemia.


• Orphanet: Rare Disease Database (ORPHA:107).


• OMIM (Online Mendelian Inheritance in Man): Entry #200100.


• Bassen, F. A., & Kornzweig, A. L. (1950). Malformation of the erythrocytes in a case of atypical retinitis pigmentosa.